{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:24:41Z","timestamp":1790630681237,"version":"4.1.0"},"reference-count":179,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50-100007, PO1-155258, RO1-50947"],"award-info":[{"award-number":["P50-100007, PO1-155258, RO1-50947"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01822","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:41:28Z","timestamp":1533861688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1"],"prefix":"10.3389","volume":"9","author":[{"given":"Yu-Tzu","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Feng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma","volume":"17","author":"Raje","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"36","author":"Anderson","year":"2018","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-16-0868","article-title":"Immune therapies in multiple myeloma","volume":"22","author":"Kumar","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2217\/fon-2017-0616","article-title":"Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA phase III study design","volume":"14","author":"Richardson","year":"2018","journal-title":"Future Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/nrc952","article-title":"Molecular mechanisms of novel therapeutic approaches for multiple myeloma","volume":"2","author":"Hideshima","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1158\/0008-5472.CAN-11-2067","article-title":"Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1","volume":"72","author":"Fowler","year":"2012","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2007-03-081240","article-title":"Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis","volume":"110","author":"Tai","year":"2007","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","article-title":"Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw","volume":"14","author":"Raje","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-3083.2010.02463.x","article-title":"Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)\/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma","volume":"72","author":"Brimnes","year":"2010","journal-title":"Scand J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/path.4860","article-title":"Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation","volume":"241","author":"De Beule","year":"2017","journal-title":"J Pathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1038\/bcj.2017.24","article-title":"Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu","volume":"7","author":"Zhang","year":"2017","journal-title":"Blood Cancer J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1359\/jbmr.2002.17.11.1921","article-title":"Role of the bone marrow microenvironment in multiple myeloma","volume":"17","author":"Roodman","year":"2002","journal-title":"J Bone Miner Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nm1417","article-title":"Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells","volume":"12","author":"Kollet","year":"2006","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1084\/jem.20110994","article-title":"Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow","volume":"209","author":"Mansour","year":"2012","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems","volume":"7","author":"Takayanagi","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1210\/er.2007-0038","article-title":"Osteoimmunology: interactions of the bone and immune system","volume":"29","author":"Lorenzo","year":"2008","journal-title":"Endocr Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11914-014-0195-2","article-title":"Bone and the innate immune system","volume":"12","author":"Charles","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1038\/sj.emboj.7601146","article-title":"T-cell tolerance or function is determined by combinatorial costimulatory signals","volume":"25","author":"Nurieva","year":"2006","journal-title":"EMBO J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","article-title":"Molecular pathways: next-generation immunotherapy \u2013 inhibiting programmed death-ligand 1 and programmed death-1","volume":"18","author":"Chen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-14-3016","article-title":"IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells","volume":"75","author":"Sun","year":"2015","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1073\/pnas.0711918105","article-title":"The PD-1\/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum","volume":"105","author":"Lazar-Molnar","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0131403","DOI":"10.1371\/journal.pone.0131403","article-title":"PD-L1 and survival in solid tumors: a meta-analysis","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.2147\/OTT.S91025","article-title":"The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis","volume":"8","author":"Huang","year":"2015","journal-title":"Onco Targets Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrclinonc.2014.221","article-title":"Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer","volume":"12","author":"Errico","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-17-0539","article-title":"Immunotherapy of lymphoma and myeloma: facts and hopes","volume":"24","author":"Pianko","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/2326-6066.CIR-15-0296","article-title":"Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1","volume":"4","author":"Ishibashi","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.4049\/jimmunol.1202005","article-title":"Programmed death receptor-1\/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma","volume":"190","author":"Kearl","year":"2013","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille","year":"1989","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/028418600750063578","article-title":"Imaging of myeloma bone disease \u2013 implications for staging, prognosis and follow-up","volume":"39","author":"Dimopoulos","year":"2000","journal-title":"Acta Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(25)00115-6","article-title":"Multiple myeloma: review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"B61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-9966-27-11","article-title":"Effect of pathologic fractures on survival in multiple myeloma patients: a case control study","volume":"27","author":"Sonmez","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","article-title":"Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease","volume":"118","author":"D\u2019Souza","year":"2011","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/blood.V97.2.346","article-title":"Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1\/fibronectin and VCAM-1","volume":"97","author":"Sanz-Rodriguez","year":"2001","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"B65","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL)","volume":"32","author":"Giuliani","year":"2004","journal-title":"Exp Hematol"},{"key":"B66","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671.014k24_671_675","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","article-title":"Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion","volume":"82","author":"Uchiyama","year":"1993","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood-2004-02-0474","article-title":"T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG\/TRAIL interaction","volume":"104","author":"Colucci","year":"2004","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.bone.2010.12.023","article-title":"RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II","volume":"48","author":"Hemingway","year":"2011","journal-title":"Bone"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.yexcr.2006.02.026","article-title":"Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation","volume":"312","author":"Nguyen","year":"2006","journal-title":"Exp Cell Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1172\/JCI80276","article-title":"Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease","volume":"126","author":"Fu","year":"2016","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2011-11-393348","article-title":"Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment","volume":"119","author":"D\u2019Souza","year":"2012","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2008-07-170464","article-title":"The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor","volume":"113","author":"Sprynski","year":"2009","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2007","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.canlet.2009.02.002","article-title":"Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma","volume":"281","author":"Jost","year":"2009","journal-title":"Cancer Lett"},{"key":"B82","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B86","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3816\/CLM.2009.n.085","article-title":"Serum levels of total-RANKL in multiple myeloma","volume":"9","author":"Jakob","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"B87","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"B88","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1006\/bbrc.2000.3379","article-title":"Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines","volume":"275","author":"Nakashima","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e41127","DOI":"10.1371\/journal.pone.0041127","article-title":"Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma","volume":"7","author":"Buckle","year":"2012","journal-title":"PLoS One"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1182\/blood-2010-04-279760","article-title":"Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration","volume":"117","author":"Moreaux","year":"2011","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","article-title":"Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma","volume":"120","author":"Tai","year":"2012","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/leu.2014.69","article-title":"A novel Bruton\u2019s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity","volume":"28","author":"Eda","year":"2014","journal-title":"Leukemia"},{"key":"B95","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","article-title":"IL-10: the master regulator of immunity to infection","volume":"180","author":"Couper","year":"2008","journal-title":"J Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3389\/fimmu.2017.01444","article-title":"Restoring natural killer cell immunity against multiple myeloma in the era of new drugs","volume":"8","author":"Pittari","year":"2017","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"12950","DOI":"10.18632\/oncotarget.2633","article-title":"LIGHT\/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease","volume":"5","author":"Brunetti","year":"2014","journal-title":"Oncotarget"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3109\/10428194.2013.825905","article-title":"Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e48871","DOI":"10.1371\/journal.pone.0048871","article-title":"Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells","volume":"7","author":"Zhuang","year":"2012","journal-title":"PLoS One"},{"key":"B100","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.exphem.2011.04.006","article-title":"Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro","volume":"39","author":"Tucci","year":"2011","journal-title":"Exp Hematol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3324\/haematol.2016.153841","article-title":"IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts","volume":"102","author":"Bolzoni","year":"2017","journal-title":"Haematologica"},{"key":"B102","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1182\/blood-2009-08-237628","article-title":"Osteoclasts are important for bone angiogenesis","volume":"115","author":"Cackowski","year":"2010","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/intimm\/dxq431","article-title":"IL-1 plays an important role in the bone metabolism under physiological conditions","volume":"22","author":"Lee","year":"2010","journal-title":"Int Immunol"},{"key":"B105","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.4049\/jimmunol.145.10.3297","article-title":"IL-6 is produced by osteoblasts and induces bone resorption","volume":"145","author":"Ishimi","year":"1990","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1074\/jbc.275.7.4858","article-title":"Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts","volume":"275","author":"Azuma","year":"2000","journal-title":"J Biol Chem"},{"key":"B107","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2003.10.005","article-title":"IL-6, RANKL, TNF-alpha\/IL-1: interrelations in bone resorption pathophysiology","volume":"15","author":"Kwan Tat","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"B108","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.rdc.2010.03.003","article-title":"Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention","volume":"36","author":"Karmakar","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"B109","doi-asserted-by":"publisher","first-page":"181849","DOI":"10.1155\/2013\/181849","article-title":"Immunological reaction in TNF-alpha-mediated osteoclast formation and bone resorption in vitro and in vivo","volume":"2013","author":"Kitaura","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1006\/bbrc.1999.1623","article-title":"Activated T lymphocytes support osteoclast formation in vitro","volume":"265","author":"Horwood","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X","article-title":"Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells","volume":"31","author":"Choi","year":"2001","journal-title":"Eur J Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"B113","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.V96.5.1873","article-title":"Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines","volume":"96","author":"Weitzmann","year":"2000","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"B115","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/35046102","article-title":"T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma","volume":"408","author":"Takayanagi","year":"2000","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood-2009-11-255026","article-title":"Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.imbio.2008.05.001","article-title":"CD137L- and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation","volume":"214","author":"Senthilkumar","year":"2009","journal-title":"Immunobiology"},{"key":"B119","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.4049\/jimmunol.0803897","article-title":"Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells","volume":"182","author":"Kiesel","year":"2009","journal-title":"J Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nature05543","article-title":"Foxp3-dependent programme of regulatory T-cell differentiation","volume":"445","author":"Gavin","year":"2007","journal-title":"Nature"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e38199","DOI":"10.1371\/journal.pone.0038199","article-title":"Osteoclast activated FoxP3+ CD8+ T-cells suppress bone resorption in vitro","volume":"7","author":"Buchwald","year":"2012","journal-title":"PLoS One"},{"key":"B122","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bone.2013.05.024","article-title":"Osteoclast-induced Foxp3+ CD8 T-cells limit bone loss in mice","volume":"56","author":"Buchwald","year":"2013","journal-title":"Bone"},{"key":"B123","doi-asserted-by":"publisher","first-page":"726","DOI":"10.4049\/jimmunol.1600253","article-title":"Osteoclast-primed Foxp3+ CD8 T cells induce T-bet, eomesodermin, and IFN-gamma to regulate bone resorption","volume":"197","author":"Shashkova","year":"2016","journal-title":"J Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.27535","article-title":"Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation","volume":"62","author":"Zaiss","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbrc.2007.04.042","article-title":"Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells","volume":"357","author":"Kim","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard.2007.080713","article-title":"CTLA-4 directly inhibits osteoclast formation","volume":"67","author":"Axmann","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B127","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/art.23138","article-title":"Treg cells suppress osteoclast formation: a new link between the immune system and bone","volume":"56","author":"Zaiss","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B128","doi-asserted-by":"publisher","first-page":"235ra60","DOI":"10.1126\/scitranslmed.3007764","article-title":"T cell costimulation molecules CD80\/86 inhibit osteoclast differentiation by inducing the IDO\/tryptophan pathway","volume":"6","author":"Bozec","year":"2014","journal-title":"Sci Transl Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/jbmr.2868","article-title":"Inflammatory osteoclasts prime TNFalpha-producing CD4(+) T cells and express CX3 CR1","volume":"31","author":"Ibanez","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br J Cancer"},{"key":"B133","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/PPO.0000000000000061","article-title":"Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation","volume":"20","author":"Sanmamed","year":"2014","journal-title":"Cancer J"},{"key":"B135","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","article-title":"Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1\/PD-L1 pathway","volume":"11","author":"Tremblay-LeMay","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"B141","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","first-page":"41228","DOI":"10.18632\/oncotarget.5682","article-title":"Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"B143","doi-asserted-by":"publisher","first-page":"e0139867","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS One"},{"key":"B144","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/15384101.2018.1442624","article-title":"Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T-cell immune responses via PD-1\/PD-L1 pathway","volume":"17","author":"Chen","year":"2018","journal-title":"Cell Cycle"},{"key":"B145","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"B146","first-page":"4417","article-title":"Eosinophils upregulate PD-L1 and PD-L2 expression to enhance the immunosuppressive microenvironment in multiple myeloma","volume":"130","author":"Driscoll","year":"2017","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/leu.2017.272","article-title":"Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy","volume":"32","author":"Kelly","year":"2018","journal-title":"Leukemia"},{"key":"B148","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/leu.2017.322","article-title":"Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma","volume":"32","author":"Ray","year":"2018","journal-title":"Leukemia"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","first-page":"24031","DOI":"10.18632\/oncotarget.15234","article-title":"Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression","volume":"8","author":"Giuliani","year":"2017","journal-title":"Oncotarget"},{"key":"B151","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B153","doi-asserted-by":"crossref","first-page":"Abstract8010","DOI":"10.1200\/JCO.2016.34.15_suppl.8010","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"34","author":"Mateos","year":"2016","journal-title":"J Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"key":"B156","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.leukres.2008.07.028","article-title":"Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6","volume":"33","author":"Hongming","year":"2009","journal-title":"Leuk Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","article-title":"Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling","volume":"113","author":"Qiang","year":"2009","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"key":"B159","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2141.2007.06829.x","article-title":"Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease","volume":"139","author":"Oyajobi","year":"2007","journal-title":"Br J Haematol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI33102","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J Clin Invest"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"B163","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp Hematol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"B165","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"B168","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clinthera.2012.02.002","article-title":"Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data","volume":"34","author":"Dempster","year":"2012","journal-title":"Clin Ther"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"B170","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res"},{"key":"B171","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"e1217374","DOI":"10.1080\/2162402X.2016.1217374","article-title":"Immunotherapies targeting CD38 in multiple myeloma","volume":"5","author":"Atanackovic","year":"2016","journal-title":"Oncoimmunology"},{"key":"B173","doi-asserted-by":"publisher","first-page":"56598","DOI":"10.18632\/oncotarget.17896","article-title":"Expression of CD38 in myeloma bone niche: a rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"B174","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"B175","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.V130.Suppl_1.740.740","article-title":"Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-Bcma CAR T cell therapy","volume":"130","author":"Berdeja","year":"2017","journal-title":"Blood"},{"key":"B176","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"23","author":"Vogl","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B177","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1182\/blood.V128.22.4507.4507","article-title":"Oncolytic reovirus immune priming: a phase 1b study of reolysin with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"128","author":"Kelly","year":"2016","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1158\/1078-0432.CCR-17-0606","article-title":"Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice","volume":"23","author":"Ahern","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B179","doi-asserted-by":"publisher","first-page":"e1431088","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01822\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:29:40Z","timestamp":1751776180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01822\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":179,"alternative-id":["10.3389\/fimmu.2018.01822"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01822","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,10]]},"article-number":"1822"}}